NASDAQ:CLSDClearside Biomedical Stock Price, Forecast & News

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CLSD stock has decreased by 17.0% and is now trading at $2.15. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clearside Biomedical.

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Clearside Biomedical.

Clearside Biomedical Inc (NASDAQ:CLSD) announced its quarterly earnings results on Friday, May, 8th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. The firm earned $4.10 million during the quarter, compared to the consensus estimate of $4 million. Clearside Biomedical had a negative return on equity of 165.19% and a negative net margin of 293.61%. View Clearside Biomedical's earnings history.

6 brokerages have issued twelve-month price objectives for Clearside Biomedical's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Clearside Biomedical's stock price to reach $5.75 in the next year. This suggests a possible upside of 167.4% from the stock's current price. View analysts' price targets for Clearside Biomedical.

News stories about CLSD stock have been trending very negative this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Clearside Biomedical earned a daily sentiment score of -3.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutClearside Biomedical.

Clearside Biomedical saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,500,000 shares, a decrease of 10.2% from the April 30th total of 1,670,000 shares. Based on an average daily volume of 524,900 shares, the days-to-cover ratio is currently 2.9 days. Approximately 4.5% of the company's stock are short sold. View Clearside Biomedical's Current Options Chain.

Some companies that are related to Clearside Biomedical include XBiotech (XBIT), Syros Pharmaceuticals (SYRS), Axovant Sciences (AXON), Progenics Pharmaceuticals (PGNX), Albireo Pharma (ALBO), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), CytomX Therapeutics (CTMX), Calithera Biosciences (CALA), Magenta Therapeutics (MGTA), Avid Bioservices (CDMO), Humanigen (HGEN), Kamada (KMDA), Spectrum Pharmaceuticals (SPPI) and Seres Therapeutics (MCRB). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), Zeltiq Aesthetics (ZLTQ), Nabriva Therapeutics (NBRV), Amarin (AMRN), Immunomedics (IMMU), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP) and Proteostasis Therapeutics (PTI).

(CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Clearside Biomedical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Carmignac Gestion (4.41%), BlackRock Inc. (1.69%), Geode Capital Management LLC (0.73%), Morgan Stanley (0.58%), Signaturefd LLC (0.27%) and Oxford Financial Group Ltd. (0.20%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Clay Thorp, George M Lasezkay and Nancy J Hutson. View institutional ownership trends for Clearside Biomedical.

CLSD stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., and UBS Group AG. View insider buying and selling activity for Clearside Biomedical.

CLSD stock was bought by a variety of institutional investors in the last quarter, including Carmignac Gestion, Morgan Stanley, Oxford Financial Group Ltd., Signaturefd LLC, Geode Capital Management LLC, Jane Street Group LLC, Fred Alger Management LLC, and BlackRock Inc.. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Clay Thorp, George M Lasezkay, and Nancy J Hutson. View insider buying and selling activity for Clearside Biomedical.

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLSD stock can currently be purchased for approximately $2.15.

Clearside Biomedical has a market capitalization of $96.47 million and generates $2.17 million in revenue each year. The company earns $-30,770,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe.

The official website for Clearside Biomedical is www.clearsidebio.com.

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]